SEQer™ antibodies represent a rapidly growing oncology-focused portfolio introducing close to 100 new antibodies every month. Developed by SDI's proprietary Genomic Antibody Technology™ (GAT), SEQer antibodies show superior performance overcoming limitations of conventional antibodies. The performance is differentiated from traditional antibodies by:
In Vivo Expression of the Immunogen:
Target protein fragment of a 100 amino acid residues is cloned into an expression vector that is delivered to primary cells of host animal resulting in a large immunogen that is synthesized, folded, and secreted utilizing the host animal's cell machinery. The immune response elicited results in exceptionally highly specific antibodies with high affinity, high titer, and high avidity to the target protein.
SDI's protein analysis algorithms selects the optimal 100 amino acid residues that ensure highly specific antibodies that are able to recognize the target protein while remaining tolerant to polymorphism, hetergenecity of glycosylation, denaturation, and mutations, than those developed against peptides/synthetic surrogates.
Multiple case studies using SEQer antibodies demonstrate consistent results in measuring differential protein expression across platforms including Protein Arrays, ELISA, WB, FACS, and others.
Highly Relevant and Exciting Content:
The SEQer portfolio is comprised of protein targeting reagents selected based upon the most current research across the most exciting fields adding 24 new antibodies every week. Explore the possibilities of driving your research with our exciting products.